Alps Advisors Inc Iovance Biotherapeutics, Inc. Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $67,834 - $93,316	-7,118 Reduced 7.63%	86,118 $825,000
Q2 2022 Aug 11, 2022	SELL	$6.38 - $18.33 $435,702 - $1.25 Million	-68,292 Reduced 42.28%	93,236 $1.03 Million
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $221,490 - $341,718	-17,891 Reduced 9.97%	161,528 $2.69 Million
Q4 2021 Feb 09, 2022	SELL	$16.55 - $27.63 $175,430 - $292,878	-10,600 Reduced 5.58%	179,419 $3.43 Million
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $211,863 - $277,244	-10,411 Reduced 5.19%	190,019 $4.69 Million
Q2 2021 Aug 11, 2021	BUY	$16.33 - $33.07 $3.27 Million - $6.63 Million	200,430 New	200,430 $5.22 Million

313

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.